ArchiMed launches takeover bid for Bomi Italia, international Medtech & Pharma services leader

The pan-European private equity healthcare specialist’s approximately €70 million bid has the support of Bomi Group’s founding family and other shareholders controlling some 70 percent of the quoted firm.

March 1, 2019 – ArchiMed’s bid for Medtech and Pharma services provider Bomi Group is subject to a number of conditions, notably that 90 percent of all shares be tendered (the threshold for delisting the firm), but it already has the support of all major shareholders of record. If successful, it will be the first transaction for ArchiMed’s new mid-market buy-and-build fund, MED Platform I (€800 million target size).

The bid for Bomi Group, listed on Borsa Italia’s AIM market translates into a per share offer of €4.00 (30.67% above yesterday’s official closing price of €3.06 and 50.38% above the six-month average price of €2.66), as well as an offer of €4,000 for each of the Company’s convertible bonds. All investors currently of record with stakes of more than 5 percent have committed to selling their full shareholdings in Bomi Group to MED Platform I. This shareholders group encompasses the Ruini family’s subsidiaries (as well as individual family members), Quaestio Capital Management Società di Gestione del Risparmio S.p.A. (on behalf of the fund Quaestio Italian Growth Fund) and First Capital S.p.A.. The three respectively own approximately 50.4% (including subsidiaries and the Ruini family members individually), 12.4% and 5.6% of Bomi Group.

If the bid is successful, Bomi Group’s management team and Chief Executive, Marco Ruini, will remain in office, with the latter reinvesting more than 40% of his proceeds from the sale back into the company for a 5 percent stake. Upon the deal’s completion, ArchiMed Partner André-Michel Ballester - who has over 30 years’ experience in the healthcare sector at major European and U.S. Medtech specialists - will become Bomi’s new Chairman.

“In addition to its sector expertise and industry networks, ArchiMed intends to make significant investments, allowing Bomi Group to expand more rapidly, both organically and through acquisitions. The entry of such a strong and specialized stakeholder represents clear added value when it comes to the fulfilment of our ambitious growth targets,” says Bomi Group Chief Executive Marco Ruini.

Founded in 1985, Bomi Group expanded rapidly over the years and today runs cutting edge transport, warehousing and supply chain management services for healthcare companies ranging from pharmaceutical and medical equipment manufacturers to hospitals, testing laboratories and outpatient service providers. Bomi Group operates in 20 countries in Europe, the Americas and Asia. Bomi Group’s first half 2018 operating revenues - the latest figures available - rose 6% to €62.2 million compared with the same period the previous year.

“Given ArchiMed’s complementary skill set, we will be able to help the management team at Bomi Group find new clients, expand into new countries and broaden their offering with new services and products for healthcare supply chain management,” says ArchiMed Partner André-Michel Ballester. “We see Bomi Group’s existing infrastructure and expertise as the key building blocks for a hard-to-replicate global buy-and-build strategy in a fast-growing space.”

 

Advisors:

  • Proxy Solicitation: Georgeson
  • Financial and Market Advisor: Equita SIM S.p.A.
  • Legal:
    • For Archimed: Gianni, Origoni, Grippo, Cappelli & Partners (GOP)
    • For the Ruini family and Bomi Group: Simmons & Simmons
  • Financial Due Diligence: KPMG
  • Tax: Bonafè Grifoni e Associati – Studio Legale Tributario

 

***

About ArchiMed – ArchiMed is a healthcare private equity investment firm headquartered in Lyon. The 30-person team (comprising 10 nationalities) was founded in 2014 by former 3i Healthcare leaders as the first independent, pan-European private equity group focused exclusively on the healthcare sector. ArchiMed invests in all healthcare sectors, including Medtech, Biopharma, and Care Services. MED Platform I is ArchiMed’s third fund and the group’s first investment vehicle to focus on healthcare’s mid-cap sector. The new fund complements the group’s MED I and MED II vehicles, which respectively raised €146 million in 2014 and €315 million in 2017. MED I and MED II focus on smaller European healthcare companies. Over the last 30 years, the ArchiMed partners have directly managed and invested in more than 40 healthcare companies throughout the world, with a combined value above €5bn.  www.archimed-group.eu

Bid information will be held in the bid documentation that will be published in the ways and in the terms and at the end of the proceedings provided for in the applicable regulatory provisions. Copy of the sent press release pursuant to art. 102 D,Lgs 58/98 as modified and to art. 37 of the Consob Regulation 11971/1999 is available on the bidder homepage www.medplatform-one.com 

 

Contacts:

Italy: Luca Manzato, luca.manzato@closetomedia.it +39 (0)2 70 00 6 237

International: David Lanchner, dlanchner@lanchner.com, +33 (0)6 33 43 50 76